Impeding the adaptive response of prostate cancer to androgen targeted therapies with relaxin receptor antagonist
Tevz, Gregor, Hossain, Akther, Bock, Nathalie, Jeet, Varinder, Bathgate, Ross A., Williams, Elizabeth D., Lehman, Melanie, Hutmacher, Dietmar, Wade, John D., & Nelson, Colleen (2015) Impeding the adaptive response of prostate cancer to androgen targeted therapies with relaxin receptor antagonist. In 2nd Prostate Cancer World Congress, 17-21 August 2015, Cairns Convention Centre, Cairns, Qld.
Androgen deprivation and androgen targeted therapies (ATT) are established treatments for prostate cancer (PCa). Although initially effective, ATT induces an adaptive response that leads to treatment resistance. Increased expression of relaxin-2 (RLN2) is an important alteration in the adaptive response. RLN2 has a well described role in PCa cell proliferation, adhesion and tumour growth. The objectives of this study were to develop cell models for studies of RLN2 signalling and to implement in vitro assays for evaluating the therapeutic properties of the unique RLN2 receptor (RXFP1) antagonist
Impact and interest:
Citation counts are sourced monthly from and citation databases.
These databases contain citations from different subsets of available publications and different time periods and thus the citation count from each is usually different. Some works are not in either database and no count is displayed. Scopus includes citations from articles published in 1996 onwards, and Web of Science® generally from 1980 onwards.
Citations counts from theindexing service can be viewed at the linked Google Scholar™ search.
Full-text downloads displays the total number of times this work’s files (e.g., a PDF) have been downloaded from QUT ePrints as well as the number of downloads in the previous 365 days. The count includes downloads for all files if a work has more than one.
Repository Staff Only: item control page